Optimizing lower intensity triplet therapy in acute myeloid leukemia: a practical guide

Area of Science:

• Hematology
• Oncology
• Clinical Pharmacology

Background:

• Venetoclax-based doublets are standard for acute myeloid leukemia (AML) in older or chemotherapy-ineligible patients.
• Many patients on doublet therapy achieve incomplete remission or relapse over time.

Purpose of the Study:

• To review the emerging evidence for frontline triplet therapy in AML.
• To provide practical recommendations for implementing triplet regimens in clinical practice.

Main Methods:

• Review of available clinical data on triplet therapy in AML.
• Analysis of dosing schedules, adverse effects, and drug interactions.

Main Results:

• Initial triplet regimens demonstrate encouraging composite complete remission and measurable residual disease negativity rates.
• Triplet therapy can facilitate allogeneic stem cell transplantation for eligible patients.
• Triplets are associated with myelosuppression and cytopenia-related toxicities.

Conclusions:

• Triplet therapy represents a promising frontline treatment strategy for specific AML populations.
• Clinical application requires careful consideration of dose adjustments and management of toxicities.
• Understanding drug-specific adverse effects and interactions is vital for safe and effective use.